ERBB2 and breast cancer: Furthermore, low ZNF385B expression significantly affected the OS in infiltrating ductal carcinoma (p = 0.00031), ER-negative BC (p = 0.04), ER-positive BC (p = 0.0025), PR-negative BC (p = 0.00015), HER-2-negative BC (p = 0.0038), and HER-2-positive BC (p = 0.0013) through subgroup analysis.